<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792830</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056365</org_study_id>
    <nct_id>NCT01792830</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients</brief_title>
  <acronym>CABG-D/C</acronym>
  <official_title>Prospective Study Aim to Determine the Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Cardiac Surgery Patients With Perioperative Hyperglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most coronary artery bypass graft surgery (CABG) patients develop high blood sugar while they
      are in the hospital. No studies have shown what the best insulin regimen is for CABG patients
      with type 2 diabetes is after going home from the hospital. Patients with high blood sugar
      and diabetes after cardiac bypass surgery will be followed for 3 months to look at how well
      their treatment(s) for diabetes work after discharge. Patients with diabetes will be
      discharged on oral antidiabetic drugs or with insulin glargine injections based on their
      sugar control. Patients with admission HbA1c &lt; 7% (a laboratory value that shows the average
      blood sugar level in the body over 3 months) will be discharged on the same diabetes
      medications that they used before coming to the hospital. Those with an HbA1c between 7% and
      9% will be discharged on insulin glargine at 50%-80% of the dose used in the hospital and
      oral antidiabetic drugs. Those with an HbA1c &gt; 9% will be discharged on glargine at 80-100%
      of the dose used in the hospital in addition to oral antidiabetic drugs or with insulin
      glargine and insulin glulisine. The primary outcome will be a change in HbA1c at 4 and 12
      weeks after discharge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospital discharge represents a critical time for ensuring a safe transition to the
      outpatient setting and reducing the need for emergency department visits and
      re-hospitalization. Poor coordination of patient care and education on insulin administration
      at the time of patient discharge to home may be associated with medical errors that may
      increase risk of hypoglycemia, hyperglycemia and hospital readmission. No prospective studies
      have examined the impact of a discharge treatment regimen after cardiac surgery. Therefore,
      this study aims to determine the efficacy and safety of an HbA1c based treatment algorithm in
      controlling blood glucose (BG) after discharge. The total duration of the study is 3 months.

      This study will include diabetic and non-diabetic subjects who participated in the American
      Diabetes Association (ADA) trial entitled &quot;Intensive Insulin Therapy in Patients Undergoing
      Coronary Artery Bypass Surgery.&quot; The ADA study is a two-arm randomized multicenter,
      open-label controlled trial aimed to determine if intensive insulin control with a BG target
      of 100-140mg/dl will reduce perioperative complications compared to a conventional BG control
      with a target of 141-180 mg/dl in hyperglycemic subjects who undergo coronary artery bypass
      graft surgery (CABG).

      Treatment recommendations at discharge:

        -  Patients with admission HbA1c &lt; 7%:

             -  Patients without a history of diabetes not requiring subcutaneous (SC) insulin in
                the hospital will be discharged on no antidiabetic therapy.

             -  Patients without a history of diabetes requiring SC insulin therapy in the hospital
                will be discharged on metformin monotherapy. A patient without a history of
                diabetes who requires SC insulin is likely a newly diagnosed diabetic. The HbA1c
                value will be important to confirm the diagnosis. If the HbA1c is &gt;6.5%, he/she
                will be diagnosed with diabetes. We do not anticipate that a patient without a
                history of diabetes and with an HbA1c &lt;6.5% will require insulin treatment or oral
                agents long-term. Those patients will be discharged on no anti diabetic therapy
                with repeated testing after discharge to rule out diabetes.

             -  Patients with a history of diabetes will be discharged on their same outpatient
                antidiabetic regimen (diet, oral antidiabetic agents and/or insulin).

             -  Assure there are no contraindications to oral agents (i.e.Thiazolidinediones (TZDs)
                and heart failure; metformin and renal failure or heart failure).

        -  Patients with Admission HbA1c between 7% and 9%:

             -  Treatment naïve patients not on any pharmacologic treatment prior to admission will
                be discharged on metformin monotherapy or a combination of metformin and a single
                dose of basal (glargine) insulin at 50% of total daily hospital dose.

             -  Patients treated with oral antidiabetic agents or glucagon-like peptide-1 (GLP1)
                analogs prior to admission will be discharged on pre-admission oral antidiabetic
                therapy plus a single dose of glargine insulin at 50% of the total daily hospital
                dose.

             -  Patients treated with combination of oral antidiabetic agents and basal insulin
                (NPH insulin also known as Neutral Protamine Hagedorn insulin, glargine, detemir)
                prior to admission will be discharged on pre-admission oral antidiabetic therapy
                plus a single dose of glargine insulin or with basal bolus insulin regimen at 50%
                of total daily hospital dose.

             -  Patients not to be treated with oral agents will be discharged on glargine
                monotherapy or basal bolus at 100% of inpatient total daily dose.

             -  Admission HbA1c ≥ 9% prior to admission:

             -  Discharge on basal bolus regimen at same inpatient total daily insulin dose.

             -  Basal insulin (glargine) once daily, at the same time of the day.

             -  Rapid-acting insulin (glulisine) before meals.

             -  Alternative treatment: If no contraindications to oral agents (i.e.,
                Thiazolidinediones (TZDs) and heart failure; metformin and renal failure) restart
                oral agents in combination to glargine once daily at 80% of total daily hospital
                dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, Measured by a Change in HbA1c Levels</measure>
    <time_frame>Hospital discharge, 1 month</time_frame>
    <description>Change in the level of HbA1c in a 1 month period after discharge from the hospital. The A1c test result is reported as a percentage. Higher percentages indicate higher blood glucose levels in the previous three months. A normal HbA1c level is below 5.7 percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission Rate to the Hospital</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of subjects that were readmitted to the hospital 3 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of subjects that experienced hypoglycemia, defined as blood glucose levels ≤70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rates for Post-operative Complications</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of complications including infections, wound infections, readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemic Events</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of subjects that experienced severe hypoglycemia, defined as blood glucose levels ≤ 40 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemic Events</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of subjects that experienced hyperglycemia, defined as blood glucose levels ≥ 140 mg/dl</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Poor Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Control HbA1c &lt; 7%</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c &lt;7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No diabetes/ Metformin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c &lt;7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic/antidiabetic regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &lt;7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No diabetes/ Insulin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c &lt;7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes/Insulin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c &gt;9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.
Patients without a history of diabetes and admission HbA1c &lt; 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.
Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.</description>
    <arm_group_label>Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%</arm_group_label>
    <arm_group_label>Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%</arm_group_label>
    <arm_group_label>No diabetes/ Metformin only</arm_group_label>
    <arm_group_label>Diabetic/antidiabetic regimen</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine insulin</intervention_name>
    <description>Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.
Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.
Patients with an HbA1c &gt; 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose.</description>
    <arm_group_label>Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%</arm_group_label>
    <arm_group_label>Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%</arm_group_label>
    <arm_group_label>Diabetic/antidiabetic regimen</arm_group_label>
    <arm_group_label>No diabetes/ Insulin only</arm_group_label>
    <arm_group_label>Diabetes/Insulin only</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glulisine</intervention_name>
    <description>Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.</description>
    <arm_group_label>Diabetes/Insulin only</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years undergoing primary coronary
             artery bypass graft surgery (CABG).

          2. Post surgical hyperglycemia (Blood glucose &gt;140 mg/dl)

          3. Patients with and without a history of type 2 diabetes

        Exclusion Criteria:

          1. Patients with severely impaired renal function (serum creatinine ≥3.0 mg/dl or a
             glomerular filtration rate &lt; 30 ml/min) or clinically significant hepatic failure.

          2. Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and
             hyperosmolar hyperglycemic states.

          3. Moribund patients and those at imminent risk of death (brain death or cardiac
             standstill).

          4. Patients or next-to-kin with mental conditions rendering the subject or family member
             unable to understand the nature, scope, and possible consequences of the study.

          5. Female subjects who are pregnant or breast-feeding at time of enrollment into the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Midtown Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>May 11, 2015</results_first_submitted>
  <results_first_submitted_qc>September 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2015</results_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Bypass Graft surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from Emory University Hospital, Emory University Hospital-Midtown and Grady Hospital from January 2013 to February 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Subjects not requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c level &lt;7% not requiring subcutaneous insulin, were discharged from the hospital without any antidiabetic therapy.</description>
        </group>
        <group group_id="P2">
          <title>No Diabetes/ Metformin Only</title>
          <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1c &lt;7% and persistent hyperglycemia requiring subcutaneous insulin, will be discharged on oral metformin.</description>
        </group>
        <group group_id="P3">
          <title>No Diabetes Insulin Group</title>
          <description>Patients with an HbA1c &lt; 7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.</description>
        </group>
        <group group_id="P4">
          <title>Diabetic/ Antidiabetic Regimen</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &lt;7% will be discharged on their same outpatient antidiabetic regimen.</description>
        </group>
        <group group_id="P5">
          <title>Diabetic/ Metformin and 50-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of the total daily hospital dose.</description>
        </group>
        <group group_id="P6">
          <title>Diabetic/ Metformin and 80-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &gt;9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of the total daily hospital dose or with a basal bolus regimen at the same inpatient total daily dose.</description>
        </group>
        <group group_id="P7">
          <title>Diabetic/Glargine and Glulisine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &gt;9% requiring subcutaneous insulin, will be discharged on basal bolus regimen at the same inpatient total daily insulin dose and glulisine before meals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Subjects not requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1C level &lt;7% not requiring subcutaneous insulin, will be discharged from the hospital without any antidiabetic therapy.</description>
        </group>
        <group group_id="B2">
          <title>No Diabetes/ Metformin Only</title>
          <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1C &lt;7% and persistent hyperglycemia requiring subcutaneous insulin, will be discharged on oral metformin.</description>
        </group>
        <group group_id="B3">
          <title>No Diabetes/ Insulin</title>
          <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1C &lt;7% and persistent hyperglycemia requiring subcutaneous insulin.</description>
        </group>
        <group group_id="B4">
          <title>Diabetic/ Antidiabetic Regimen</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &lt;7% will be discharged on their same outpatient antidiabetic regimen.</description>
        </group>
        <group group_id="B5">
          <title>Diabetic/ Metformin and 50-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C between 7% and 9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of the total daily hospital dose.</description>
        </group>
        <group group_id="B6">
          <title>Diabetic/ Metformin and 80-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &gt;9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of the total daily hospital dose or with a basal bolus regimen at the same inpatient total daily dose.</description>
        </group>
        <group group_id="B7">
          <title>Diabetic/ Glargine and Glulisine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &gt;9% requiring subcutaneous insulin, will be discharged on basal bolus regimen at the same inpatient total daily insulin dose and glulisine before meals.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="41"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy, Measured by a Change in HbA1c Levels</title>
        <description>Change in the level of HbA1c in a 1 month period after discharge from the hospital. The A1c test result is reported as a percentage. Higher percentages indicate higher blood glucose levels in the previous three months. A normal HbA1c level is below 5.7 percent.</description>
        <time_frame>Hospital discharge, 1 month</time_frame>
        <population>Most patients that completed the discharge part did so over the phone. Some of the subjects who came to the hospital for their visit had trouble getting their blood drawn for HbA1c levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Control HbA1C &lt; 7%</title>
            <description>Subjects not requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1C &lt;7% not requiring subcutaneous insulin in the hospital were discharged on no antidiabetic therapy.</description>
          </group>
          <group group_id="O2">
            <title>No Diabetes, Metformin Only</title>
            <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1C &lt;7% were discharged on oral metformin.</description>
          </group>
          <group group_id="O3">
            <title>No Diabetes Insulin Group</title>
            <description>Patients with an A1C &lt; 7% and persistent hyperglycemia requiring SC insulin therapy in the hospital were discharged on oral metformin.</description>
          </group>
          <group group_id="O4">
            <title>Diabetic HbA1C &lt;7% Metformin</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &lt;7% were discharged on their same outpatient antidiabetic regimen (diet, oral antidiabetic agents and/or insulin).
Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels were used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.</description>
          </group>
          <group group_id="O5">
            <title>Diabetic HbA1C &lt;7% Glargine</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &lt;7% were discharged on their same outpatient antidiabetic regimen (diet, oral antidiabetic agents and/or insulin).
During treatment initiation and dose titration, the patient's blood glucose levels were used to determine the therapeutic response to glargine and identify the minimum effective dose for the patient. Glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar levels.</description>
          </group>
          <group group_id="O6">
            <title>Diabetic HbA1C 7%- 9% Metformin</title>
            <description>Subjects requiring coronary artery bypass graft surgery with a history of diabetes with HbA1C between 7% and 9% requiring in hospital subcutaneous insulin were discharged on oral metformin and a single dose of glargine at 50% of total daily hospital dose. Metformin was given in divided doses with meals.</description>
          </group>
          <group group_id="O7">
            <title>Diabetic HbA1C 7%-9% Metformin + Glargine</title>
            <description>Patients treated with combination of oral antidiabetic agents and basal insulin (NPH, glargine, detemir) prior to admission were discharged on pre-admission oral antidiabetic therapy plus a single dose of glargine insulin or with basal bolus insulin regimen at 50% of total daily hospital dose.</description>
          </group>
          <group group_id="O8">
            <title>Diabetic HbA1C 7%-9% Glargine</title>
            <description>Patients with HbA1C between 7% and 9% requiring subcutaneous insulin therapy were discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose given once a day at the same time every day.</description>
          </group>
          <group group_id="O9">
            <title>Diabetic HbA1C &gt;9% Metformin + Insulin</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &gt; 9% were discharged on oral metformin and glargine insulin taken daily at the same time of day; or, basal bolus insulin regimen.</description>
          </group>
          <group group_id="O10">
            <title>Diabetic HbA1C &gt;9% Glulisine</title>
            <description>Subjects requiring coronary artery bypass graft surgery with a history of diabetes with HbA1C between 7% and 9% requiring in hospital subcutaneous insulin were discharged on glulisine, a rapid-acting insulin taken before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy, Measured by a Change in HbA1c Levels</title>
          <description>Change in the level of HbA1c in a 1 month period after discharge from the hospital. The A1c test result is reported as a percentage. Higher percentages indicate higher blood glucose levels in the previous three months. A normal HbA1c level is below 5.7 percent.</description>
          <population>Most patients that completed the discharge part did so over the phone. Some of the subjects who came to the hospital for their visit had trouble getting their blood drawn for HbA1c levels.</population>
          <units>percent of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="0.43"/>
                    <measurement group_id="O2" value="5.2" spread="0.00"/>
                    <measurement group_id="O3" value="5.5" spread="0.5"/>
                    <measurement group_id="O4" value="5.8" spread="0.5"/>
                    <measurement group_id="O5" value="6.9" spread="1.6"/>
                    <measurement group_id="O6" value="6.1" spread="2.6"/>
                    <measurement group_id="O7" value="6.3" spread="0.89"/>
                    <measurement group_id="O8" value="6.6" spread="0.7"/>
                    <measurement group_id="O9" value="8.6" spread="1.9"/>
                    <measurement group_id="O10" value="6.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission Rate to the Hospital</title>
        <description>Number of subjects that were readmitted to the hospital 3 months after discharge</description>
        <time_frame>3 months after discharge</time_frame>
        <population>The numbers listed are reflective of the total number of subjects who remained in the study at the 3 months after discharge time period. Many of the subjects were lost to follow up or never returned for their post-operative visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Control HbA1C &lt; 7%</title>
            <description>Subjects not requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1C &lt;7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.</description>
          </group>
          <group group_id="O2">
            <title>No Diabetes, Metformin Only</title>
            <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1C &lt;7% and persistent hyperglycemia requiring subcutaneous insulin, will be discharged on oral metformin.</description>
          </group>
          <group group_id="O3">
            <title>No Diabetes Insulin Group</title>
            <description>Patients with an A1C &lt; 7% and persistent hyperglycemia requiring SC insulin therapy in the hospital were discharged on oral metformin.</description>
          </group>
          <group group_id="O4">
            <title>Diabetic HbA1C &lt;7% Metformin</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &lt;7% will be discharged on their same outpatient antidiabetic regimen (diet, oral antidiabetic agents and/or insulin).
Metformin: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.
Patients without a history of diabetes and admission HbA1C &lt; 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.
Treatment naïve patients with an HbA1C between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.</description>
          </group>
          <group group_id="O5">
            <title>Diabetic HbA1C &lt;7% Glargine</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &lt;7% will be discharged on their same outpatient antidiabetic regimen (diet, oral antidiabetic agents and/or insulin).
Metformin: Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient. Treatment naïve patients with an HbA1C between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin.</description>
          </group>
          <group group_id="O6">
            <title>Diabetic HbA1C 7%- 9% Metformin</title>
            <description>Subjects requiring coronary artery bypass graft surgery with a history of diabetes with HbA1C between 7% and 9% requiring in hospital subcutaneous insulin will be discharged on oral metformin and a single dose of glargine at 50% of total daily hospital dose. Metformin is given in divided doses with meals.</description>
          </group>
          <group group_id="O7">
            <title>Diabetic HbA1C 7%-9% Metformin + Glargine</title>
            <description>Patients treated with combination of oral antidiabetic agents and basal insulin (NPH, glargine, detemir) prior to admission will be discharged on pre-admission oral antidiabetic therapy plus a single dose of glargine insulin or with basal bolus insulin regimen at 50% of total daily hospital dose.</description>
          </group>
          <group group_id="O8">
            <title>Diabetic HbA1C 7%-9% Glargine</title>
            <description>Patients with HbA1C between 7% and 9% requiring subcutaneous insulin therapy will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose given once a day at the same time every day.</description>
          </group>
          <group group_id="O9">
            <title>Diabetic HbA1C &gt;9% Metformin + IInsulin</title>
            <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1C &gt; 9% will be discharged on oral metformin and glargine insulin to be taken daily at the same time of day; or, basal bolus insulin regimen.</description>
          </group>
          <group group_id="O10">
            <title>Diabetic HbA1C &gt;9% Glulisine</title>
            <description>Subjects requiring coronary artery bypass graft surgery with a history of diabetes with HbA1C between 7% and 9% requiring in hospital subcutaneous insulin will be discharged on glulisine, a rapid-acting insulin to be taken before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission Rate to the Hospital</title>
          <description>Number of subjects that were readmitted to the hospital 3 months after discharge</description>
          <population>The numbers listed are reflective of the total number of subjects who remained in the study at the 3 months after discharge time period. Many of the subjects were lost to follow up or never returned for their post-operative visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events</title>
        <description>Number of subjects that experienced hypoglycemia, defined as blood glucose levels ≤70 mg/dl</description>
        <time_frame>3 months after discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rates for Post-operative Complications</title>
        <description>Number of complications including infections, wound infections, readmissions</description>
        <time_frame>3 months after discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemic Events</title>
        <description>Number of subjects that experienced severe hypoglycemia, defined as blood glucose levels ≤ 40 mg/dl</description>
        <time_frame>3 months after discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperglycemic Events</title>
        <description>Number of subjects that experienced hyperglycemia, defined as blood glucose levels ≥ 140 mg/dl</description>
        <time_frame>3 months after discharge</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month after hospital discharge</time_frame>
      <desc>The total number of subjects in the No Diabetes group= 7, which is the sum of the subjects (No diabetes/Metformin=3 and No Diabetes/Insulin group=4 from Participant Flow) who did not have diabetes, but received Metformin.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Subjects not requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c level &lt;7% not requiring subcutaneous insulin, will be discharged from the hospital without any antidiabetic therapy.</description>
        </group>
        <group group_id="E2">
          <title>No Diabetes/ Metformin Only</title>
          <description>Subjects requiring coronary artery bypass graft (CABG) surgery with no history of diabetes with HbA1c &lt;7% and persistent hyperglycemia requiring subcutaneous insulin, will be discharged on oral metformin.</description>
        </group>
        <group group_id="E3">
          <title>Diabetic/ Antidiabetic Regimen</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &lt;7% will be discharged on their same outpatient antidiabetic regimen.</description>
        </group>
        <group group_id="E4">
          <title>Diabetic/ Metformin and 50-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of the total daily hospital dose.</description>
        </group>
        <group group_id="E5">
          <title>Diabetic/ Metformin and 80-Glargine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &gt;9% requiring subcutaneous insulin, will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of the total daily hospital dose or with a basal bolus regimen at the same inpatient total daily dose.</description>
        </group>
        <group group_id="E6">
          <title>Diabetic/ Glargine and Glulisine</title>
          <description>Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c &gt;9% requiring subcutaneous insulin, will be discharged on basal bolus regimen at the same inpatient total daily insulin dose and glulisine before meals.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Death during hospital readmission</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Necrotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ulcers</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach virus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study had participants from other states who lived more than 50 miles away from the hospitals and did not return for their post-operative care or 12 week follow up. Some subjects preferred to complete follow ups via phone and no blood was drawn.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

